Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11984370 | 1.00 | TDP1 (0.37) | TDP1FOLH1ATMCA12CA1 | |
| SCHEMBL23780010 | 0.96 | EPHX2 (0.38) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL23780008 | 0.96 | EPHX2 (0.38) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL18396048 | 0.90 | FOLH1 (0.41) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL18396046 | 0.90 | FOLH1 (0.41) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL30031700 | 0.90 | FOLH1 (0.41) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL16010862 | 0.90 | FOLH1 (0.41) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL16010863 | 0.90 | FOLH1 (0.41) | TDP1FOLH1ATMEPHX2POLB | |
| SCHEMBL22839983 | 0.90 | TDP1 (0.38) | TDP1FOLH1CA12CA1CA2 | |
| SCHEMBL22878289 | 0.89 | FOLH1 (0.47) | TDP1FOLH1ATMCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534429-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2023-03-30 | — | — | US | disclosed |
| EP-3699162-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3335736-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3699162-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10647666-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10640461-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20160279235-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2016-09-29 | — | — | US | disclosed |
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2942065-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2097111-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2097111-A2 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
| US-20160279235-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
| US-10647666-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
| US-12534429-B2 | Heterodimers of glutamic acid | FOLH1, GLUL, SLC25A13 | TDP1 3697/4885FOLH1 1/4885ATM 3882/4885 |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | TDP1 3431/4885FOLH1 5/4885ATM 4518/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | TDP1 3396/4885FOLH1 5/4885ATM 4512/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | TDP1 3189/4885FOLH1 5/4885ATM 4548/4885 |
| US-10640461-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | TDP1 3411/4885FOLH1 5/4885ATM 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.